{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:36:10Z","timestamp":1790750170470,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Nipah virus (NiV) and Hendra virus (HeV) are newly emerging dangerous zoonotic pathogens of the <jats:italic>Henipavirus<\/jats:italic> genus of the <jats:italic>Paramyxoviridae<\/jats:italic> family. NiV and HeV (HNVs) which are transmitted by bats cause acute respiratory disease and fatal encephalitis in humans. To date, as there is a lack of antiviral drugs or effective antiviral therapies, the development of vaccines against those two viruses is of primary importance, and the immunogen design is crucial to the success of vaccines. In this study, the full-length protein (G), the ectodomain (Ge) and the head domain (Gs) of NiV attachment glycoprotein were delivered by the replication-defective type 5 adenovirus vector (Ad5) respectively, and the recombinant Ad5-NiV vaccine candidates (Ad5-NiVG, Ad5-NiVGe and Ad5-NiVGs) were constructed and their immunogenicity were evaluated in mice. The results showed that all the vaccine candidates stimulated specific humoral and cellular immune responses efficiently and rapidly against both NiV and HeV, and the Ad5-NiVGe elicited the strongest immune responses after a single-dose immunization. Furthermore, the potent conserved T-cell epitope DTLYFPAVGFL shared by NiV and HeV was identified in the study, which may provide valid information on the mechanism of HNVs-specific cellular immunity. In summary, this study demonstrates that the Ad5-NiVGe could be a potent vaccine candidate against HNVs by inducing robust humoral and cellular immune responses.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1180344","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:36:06Z","timestamp":1690472166000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Nipah virus attachment glycoprotein ectodomain delivered by type 5 adenovirus vector elicits broad immune response against NiV and HeV"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaoyan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1128\/JVI.00469-10","article-title":"A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade","volume":"84","author":"Aguilar","year":"2010","journal-title":"J. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1146\/annurev-virology-021920-113833","article-title":"Vaccines to emerging viruses: nipah and hendra","volume":"7","author":"Amaya","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/bioinformatics\/btv639","article-title":"Gapped sequence alignment using artificial neural networks: application to the MHC class I system","volume":"32","author":"Andreatta","year":"2016","journal-title":"Bioinf. (Oxford England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nsmb.1435","article-title":"Structural basis of nipah and hendra virus attachment to their cell-surface receptor ephrin-B2","volume":"15","author":"Bowden","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3201\/eid1202.051247","article-title":"Nipah virus-associated encephalitis outbreak, siliguri, India","volume":"12","author":"Chadha","year":"2006","journal-title":"Emerg. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S1386-6532(02)00268-8","article-title":"Nipah virus outbreak in Malaysia","volume":"26","author":"Chua","year":"2003","journal-title":"J. Clin. Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16002","DOI":"10.1038\/npjvaccines.2016.2","article-title":"Peri-exposure protection against nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine","volume":"1","author":"DeBuysscher","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-1115-8_19","article-title":"T-Cell epitope prediction methods: an overview","volume":"1184","author":"Desai","year":"2014","journal-title":"Methods Mol. Biol. (Clifton NJ)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1286-4579(01)01384-3","article-title":"The natural history of hendra and nipah viruses","volume":"3","author":"Field","year":"2001","journal-title":"Microbes Infect."},{"key":"B11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-021-00284-w","article-title":"A single dose investigational subunit vaccine for human use against nipah virus and hendra virus","volume":"6","author":"Geisbert","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/S1473-3099(21)00400-X","article-title":"Medical countermeasures against henipaviruses: a review and public health perspective","volume":"22","author":"G\u00f3mez Rom\u00e1n","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"D783","DOI":"10.1093\/nar\/gkz1029","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza Faviel","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1128\/JVI.78.2.834-840.2004","article-title":"Nipah virus: vaccination and passive protection studies in a hamster model","volume":"78","author":"Guillaume","year":"2004","journal-title":"J. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3201\/eid1307.061128","article-title":"Person-to-person transmission of nipah virus in a Bangladeshi community","volume":"13","author":"Gurley","year":"2007","journal-title":"Emerg. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3201\/eid2204.151747","article-title":"Nipah virus transmission from bats to humans associated with drinking traditional liquor made from date palm sap, Bangladesh, 2011-2014","volume":"22","author":"Islam","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.12703\/r\/10-74","article-title":"Recent advances in combating nipah virus","volume":"10","author":"Johnson","year":"2021","journal-title":"Faculty Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":":26","DOI":"10.3390\/v12010026","article-title":"A soluble version of nipah virus glycoprotein G delivered by vaccinia virus MVA activates specific CD8 and CD4 T cells in mice","volume":"12","author":"Kalodimou","year":"2019","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/0014-5793(90)80535-Q","article-title":"A semi-empirical method for prediction of antigenic determinants on protein antigens","volume":"276","author":"Kolaskar","year":"1990","journal-title":"FEBS Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1086\/338818","article-title":"Nipah virus encephalitis outbreak in Malaysia","author":"Lam","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/v12040480","article-title":"Fc-based recombinant henipavirus vaccines elicit broad neutralizing antibody responses in mice","volume":"12","author":"Li","year":"2020","journal-title":"Viruses"},{"key":"B23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.pep.2013.05.009","article-title":"Use of baculovirus expression system for generation of virus-like particles: successes and challenges","volume":"90","author":"Liu","year":"2013","journal-title":"Protein Expression Purification"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772864","article-title":"Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate nipah vaccine","volume":"12","author":"Loomis","year":"2021","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00842","article-title":"Structure-based design of nipah virus vaccines: a generalizable approach to paramyxovirus immunogen development","volume":"11","author":"Loomis","year":"2020","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2013.07.011","article-title":"The pandemic potential of nipah virus","volume":"100","author":"Luby","year":"2013","journal-title":"Antiviral Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6632","DOI":"10.1128\/JVI.00076-12","article-title":"Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation","volume":"86","author":"Maar","year":"2012","journal-title":"J. Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1016\/j.vaccine.2008.05.016","article-title":"A recombinant subunit vaccine formulation protects against lethal nipah virus challenge in cats","volume":"26","author":"McEachern","year":"2008","journal-title":"Vaccine"},{"key":"B29","unstructured":"Saved studies"},{"key":"B30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3201\/eid2003.131159","article-title":"Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health","volume":"20","author":"Middleton","year":"2014","journal-title":"Emerg. Infect. Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2567957","DOI":"10.1155\/2020\/2567957","article-title":"Epitope-based peptide vaccine against glycoprotein G of nipah henipavirus using immunoinformatics approaches","volume":"2020","author":"Mohammed","year":"2020","journal-title":"J. Immunol. Res."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010658","article-title":"Recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential","volume":"18","author":"Monath","year":"2022","journal-title":"PloS Pathog."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03222-21","article-title":"Novel roles of the nipah virus attachment glycoprotein and its mobility in early and late membrane fusion steps","volume":"13","author":"Ortega","year":"2022","journal-title":"mBio"},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1743-422X-10-237","article-title":"Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against nipah virus disease for over 12 months","volume":"10","author":"Pallister","year":"2013","journal-title":"Virol. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.compbiolchem.2016.03.001","article-title":"Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic henipavirus","volume":"61","author":"Parvege","year":"2016","journal-title":"Comput. Biol. Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"18.9.1","DOI":"10.1002\/cpim.12","article-title":"TepiTool: a pipeline for computational prediction of T cell epitope candidates","volume":"114","author":"Paul","year":"2016","journal-title":"Curr. Protoc. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1016\/j.vaccine.2016.08.028","article-title":"Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response","volume":"34","author":"Pickering","year":"2016","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis699","article-title":"Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines","volume":"207","author":"Ploquin","year":"2013","journal-title":"J. Infect. Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1016\/j.vaccine.2015.03.089","article-title":"Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from nipah virus disease","volume":"33","author":"Prescott","year":"2015","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/prot.21078","article-title":"Prediction of continuous b-cell epitopes in an antigen using recurrent neural network","volume":"65","author":"Saha","year":"2006","journal-title":"Proteins"},{"key":"B42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/978-1-60327-118-9_29","article-title":"Prediction methods for b-cell epitopes","volume":"409","author":"Saha","year":"2007","journal-title":"Methods Mol. Biol. (Clifton NJ)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2680160","DOI":"10.1155\/2017\/2680160","article-title":"Fundamentals and methods for T- and b-cell epitope prediction","volume":"2017","author":"Sanchez-Trincado","year":"2017","journal-title":"J. Immunol. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":":9330","DOI":"10.3390\/ijms22179330","article-title":"Proteome based approach defines candidates for designing a multitope vaccine against the nipah virus","volume":"22","author":"Soltan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":":465","DOI":"10.3390\/v12040465","article-title":"Nipah virus: past outbreaks and future containment","volume":"12","author":"Soman Pillai","year":"2020","journal-title":"Viruses"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0007462","article-title":"A single-dose ChAdOx1-vectored vaccine provides complete protection against nipah Bangladesh and Malaysia in Syrian golden hamsters","volume":"13","author":"van Doremalen","year":"2019","journal-title":"PloS Negl. Trop. Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jviromet.2006.11.023","article-title":"Duplex nested RT-PCR for detection of nipah virus RNA from urine specimens of bats","volume":"141","author":"Wacharapluesadee","year":"2007","journal-title":"J. Virol. Methods"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1126\/science.abm5561","article-title":"Architecture and antigenicity of the nipah virus attachment glycoprotein","volume":"375","author":"Wang","year":"2022","journal-title":"Sci. (New York NY)"},{"key":"B49","unstructured":"Prioritizing diseases for research and development in emergency contexts2021"},{"key":"B50","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1177\/0300985810378648","article-title":"Henipavirus: a review of laboratory animal pathology","volume":"47","author":"Williamson","year":"2010","journal-title":"Veterinary Pathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"9953","DOI":"10.1073\/pnas.0804797105","article-title":"Host cell recognition by the henipaviruses: crystal structures of the nipah G attachment glycoprotein and its complex with ephrin-B3","volume":"105","author":"Xu","year":"2008","journal-title":"Proc. Natl. Acad. Sci. United States America"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.818545","article-title":"Nipah virus outbreak in kerala state, India amidst of COVID-19 pandemic","volume":"10","author":"Yadav","year":"2022","journal-title":"Front Public Health"},{"key":"B53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet (London England)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet (London England)"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet (London England)"},{"key":"B56","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet (London England)"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1180344\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T15:36:11Z","timestamp":1690472171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1180344\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":56,"alternative-id":["10.3389\/fcimb.2023.1180344"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1180344","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"article-number":"1180344"}}